IL17A and COVID-19: In fact, eosinopenia correlates to poor outcome in patients with COVID-19, and the restoration of eosinophil numbers is linked to disease improvement (89) and T2-low asthma endotype may correlate with severe COVID-19, as IL-17 (a cytokine that participates in T2-low asthma pathogenesis) drives the immunopathogenesis of ARDS in patients with severe COVID-19 (82).